Business context and reporting period
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on cellular metabolism. This Form 10-K covers the fiscal year ended December 31, 2020; it also reports unaudited fourth-quarter results. At filing, the company operated oncology and genetically defined disease (GDD) programs, but had agreed to sell its oncology business to Servier, subject to closing conditions.
Financial results and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Total revenue | $203.2 million | $117.9 million |
| Product revenue, net | $121.1 million | $59.9 million |
| Operating expenses | $519.3 million | $544.2 million |
| Loss from operations | $316.1 million | $426.3 million |
| Net loss | $327.4 million | $411.5 million |
| Net loss per share, diluted | $4.74 | $6.86 |
| Cash used in operating activities | $290.8 million | $370.6 million |
Revenue growth reflected higher TIBSOVO sales and collaboration revenue. The filing does not provide a clear consolidated operating-margin figure. Fourth-quarter 2020 revenue was $44.0 million and net loss was $97.7 million, versus $35.4 million and $102.4 million, respectively, in fourth-quarter 2019.
At year-end, cash, cash equivalents and marketable securities totaled $670.5 million; total assets were $853.0 million and total liabilities were $453.5 million. The balance sheet included a $261.3 million liability from the sale of future IDHIFA revenue, accounted for as debt financing, and $104.6 million of operating lease liabilities. No conventional borrowings are identified in the provided financial statements. The company reported an accumulated deficit of $1.84 billion.
Financing cash flow included $250.5 million net proceeds from the IDHIFA royalty transaction. The company said existing liquidity, anticipated product revenue, interest income and collaboration reimbursements—excluding Servier proceeds and additional milestones—were expected to fund operations to the end of 2022.
Material changes versus the prior comparable period
- Revenue increased 72% year over year, while operating expenses declined 5%; the operating and net losses narrowed.
- Product revenue more than doubled, primarily from increased TIBSOVO sales. Research and development expense fell $43.4 million, while selling, general and administrative expense rose $17.0 million.
- Agios received $255 million from Royalty Pharma for IDHIFA royalty and certain milestone rights. The transaction was recorded as a liability, with $17.8 million of non-cash interest expense in 2020.
- Celgene declined to extend or continue the 2016 research collaboration and declined its option on AG-270. Agios consequently lost eligibility for certain potential milestone payments, including up to $168.8 million relating to AG-270.
- Agios halted internal AG-636 development due to limited trial enrollment. It also withdrew the TIBSOVO European marketing application after EMA feedback that the available single-arm trial data did not support a positive benefit-risk balance.
Outlook, risks and unusual items
The proposed Servier transaction provides for $1.8 billion cash at closing, subject to adjustments; a possible $200 million payment if specified vorasidenib approval criteria are met by January 1, 2027; and royalties on U.S. TIBSOVO and vorasidenib sales. Closing required stockholder and regulatory approvals and was expected at the end of the first quarter or beginning of the second quarter of 2021. The filing does not establish that the transaction had closed.
Management expected to focus the remaining company on GDDs, including mitapivat and AG-946, and stated that, after closing and shareholder returns, capital was expected to support operations through major catalysts and to cash-flow positivity without additional equity. These are forward-looking expectations, not guaranteed outcomes. Mitapivat’s pivotal ACTIVATE trial met its primary endpoint; the company reported in January 2021 that ACTIVATE-T also met its primary endpoint. Agios planned U.S. and EU regulatory submissions for mitapivat in 2021 and a potential 2022 launch. COVID-19 disrupted clinical enrollment and delayed some development and regulatory timelines.
Key risks include failure or delay of the Servier transaction, uncertain working-capital adjustments and contingent consideration, reduced diversification after the sale, continued operating losses, clinical and regulatory uncertainty, competition, reliance on third-party manufacturers and collaborators, and reimbursement and pricing pressures. The transaction could also reduce revenue: Agios would cease selling TIBSOVO and transfer IDHIFA co-commercialization rights if it closed.
No material legal proceedings or off-balance-sheet arrangements were reported. The auditor issued an unqualified opinion on the financial statements and internal control over financial reporting; the filing highlights significant judgment in accounting for and valuing the IDHIFA royalty-sale liability.
Important facts for investors to verify
- Whether the Servier sale closed, the final cash proceeds after adjustments, and the actual allocation of proceeds to operations and stockholder returns.
- Mitapivat submission, regulatory-review and launch timing, and the full clinical data supporting the reported trial endpoints.
- Future TIBSOVO and IDHIFA-related revenues, including Servier royalties, IDHIFA royalty-sale payments and the remaining contingent milestone.
- Cash burn and liquidity after the oncology divestiture and any shareholder distributions; the runway estimate depends on management assumptions.
- Clinical, regulatory and enrollment progress for the remaining GDD pipeline, together with COVID-19, manufacturing and reimbursement risks.